Lipum (publ) recruited Dr. Fredrik Seijsing to strengthen the preclinical development of SOL-116. Dr. Seijsing has a PhD in Molecular Bioscience from Wenner-Gren's institute at Stockholm University and a master's degree in Medicinal biotechnology from Umeå University. He also has industry experience as process engineer from Cobra Biologics.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.45 SEK | -3.98% |
|
-2.87% | +29.60% |
06-18 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
05-28 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.60% | 17.57M | |
+2.99% | 94.76B | |
-3.68% | 37.58B | |
-11.61% | 33.3B | |
+75.16% | 27.92B | |
-13.40% | 15.85B | |
-2.29% | 13.79B | |
-12.21% | 11.51B | |
+188.83% | 10.9B | |
-53.94% | 9.27B |
- Stock Market
- Equities
- LIPUM Stock
- News Lipum AB
- Lipum Recruits Fredrik Seijsing as Scientist